芪仙骨合剂治疗脾肾两虚夹瘀型糖尿病性骨质疏松症的临床研究

发布时间：2018-01-31 22:50

本文关键词： 芪仙骨合剂糖尿病性骨质疏松症中医证候积分骨密度　出处：《宁夏医科大学》2017年硕士论文　论文类型：学位论文

【摘要】：目的通过观察芪仙骨合剂对糖尿病性骨质疏松症患者中医证候积分、骨密度、骨代谢生化指标、血糖、血液流变学及血脂等指标,以探讨其临床疗效及其安全性。方法选择2015年6月~2016年3月就诊于我院,符合诊断标准的住院患者70例。分组采用随机单盲法,分为治疗组与对照组,每组各35例,均予两组患者基础治疗。在此基础上,对照组给予口服骨疏康胶囊治疗,治疗组给予口服芪仙骨合剂治疗,疗程为180天。试验结束时,观察并比较两组治疗前、后的中医证候积分、骨密度、骨代谢生化指标、血糖、血脂、血液流变学等各项指标,并进行评价,统计软件采用SPSS19.0进行数据分析。结果1.通过对70例患者的观察,两组在治疗前对比一般资料具有可比性,无统计学差异(P0.05)。总有效率比较,对照组总有效率为65.71%,治疗组总有效率为88.57%,差异有统计学意义(P0.05),说明芪仙骨合剂总体临床疗效优于骨疏康胶囊。2.中医证候积分的比较,治疗组与对照组在治疗后中医症候积分均有减少(P0.05),两组间比较,治疗组中医症候积分较对照组减少明显(P0.05),说明芪仙骨合剂在改善患者临床症状方面较骨疏康胶囊疗效更佳。3.骨密度的比较,治疗组与对照组在治疗后,患者骨密度均提高,两组间比较,治疗组骨密度较对照组增加明显,差异有统计学意义(P0.05);因此,在增加患者骨密度方面治疗组疗效显著。4.经过治疗后两组患者血流变学指标及总胆固醇、甘油三酯、低密度脂蛋白均有所改善,且治疗组较对照组疗效更佳,差异有统计学意义(P0.05)。5.在实验过程中无不良反应,且无不良事件发生,治疗期间的安全性指标未见显著性改变。结论运用芪仙骨合剂治疗脾肾两虚夹瘀型糖尿病性骨质疏松症,可显著改善患者的临床症状,改善骨密度、脂代谢及糖代谢,未见不良反应及不良事件,说明芪仙骨合剂治疗糖尿病性骨质疏松症安全有效。
[Abstract]:Objective to observe the TCM syndromes integral, bone mineral density, biochemical index of bone metabolism, blood sugar, hemorheology and blood lipid in patients with diabetic osteoporosis treated with Qixianguo mixture. Methods from June 2015 to March 2016, 70 inpatients who met the diagnostic criteria were selected. Divided into treatment group and control group, each group of 35 cases, both groups were given basic treatment. On this basis, the control group was given oral Gushukang capsule treatment, the treatment group was given oral Qi-Xiangugu mixture treatment. The course of treatment was 180 days. At the end of the experiment, the TCM syndromes score, bone mineral density, bone metabolism biochemical index, blood glucose, blood lipid and hemorheology were observed and compared before and after treatment in the two groups. Statistical software SPSS19.0 data analysis. Results 1. Through the observation of 70 patients, the two groups before treatment compared with the general data are comparable. 2. The total effective rate was 65.71 in the control group and 88.57 in the treatment group. The difference was statistically significant (P 0.05). It shows that the overall clinical efficacy of Qixian Gu mixture is better than that of Guxukang capsule .2.Compared with the traditional Chinese medicine syndromes integral, the treatment group and the control group have reduced the TCM symptom score after treatment, and the comparison between the two groups. Compared with the control group, the TCM symptom score of the treatment group decreased significantly (P 0.05), which indicated that Qixian Gu mixture was better than Guxukang capsule in improving the clinical symptoms of the patients. After treatment, the BMD of the patients in the treatment group and the control group were all increased. Compared with the control group, the BMD in the treatment group was significantly higher than that in the control group, and the difference was statistically significant (P 0.05). Therefore, in the increase of bone mineral density in the treatment group significantly. 4. After treatment, the two groups of patients with hemorheology and total cholesterol, triglyceride, low density lipoprotein have improved. The therapeutic effect of the treatment group was better than that of the control group, and the difference was statistically significant (P 0.05). There were no adverse reactions and no adverse events occurred in the course of the experiment. Conclusion Qixiangui mixture can significantly improve the clinical symptoms and bone mineral density in treating diabetic osteoporosis with deficiency of spleen and kidney. Lipid metabolism and glucose metabolism, no adverse reactions and adverse events, which indicated that Qixianguji was safe and effective in the treatment of diabetic osteoporosis.
【学位授予单位】：宁夏医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R259

【参考文献】